Shilpaa Mukundan1, Kriti Sharma1, Kim Honselmann2, Amy Singleton3, Andrew Liss2, Biju Parekkadan1,3,4. 1. 1 Department of Biomedical Engineering, Rutgers, The State University of New Jersey, Piscataway, NJ, USA. 2. 2 Department of Surgery, Andrew L. Warshaw Institute for Pancreatic Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 3. 3 Center for Surgery, Bioengineering, and Innovation, Department of Surgery, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, MA, USA. 4. 4 Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Abstract
Pancreatic cancer is one of the most aggressive cancers with a 5-year patient survival rate of 8.2% and limited availability of therapeutic agents to target metastatic disease. Pancreatic cancer is characterized by a dense stromal cell population with unknown contribution to the progression or suppression of tumor growth. In this study, we describe a microengineered tumor stromal assay of patient-derived pancreatic cancer cells to study the heterotypic interactions of patient pancreatic cancer cells with different types of stromal fibroblasts under basal and drug-treated conditions. The population dynamics of tumor cells in terms of migration and viability were visualized as a functional end point. Coculture with cancer-associated fibroblasts increased the migration of cancer cells when compared to dermal fibroblasts. Finally, we imaged the response of a bromodomain and extraterminal inhibitor on the viability of pancreatic cancer clusters surrounding by stroma in microengineered tumor stromal assay. We visualized a codynamic reduction in both cancer and stromal cells with bromodomain and extraterminal treatment compared to the dimethyl sulfoxide-treated group. This study demonstrates the ability to engineer tumor-stromal assays with patient-derived cells, study the role of diverse types of stromal cells on cancer progression, and precisely visualize a coculture during the screening of therapeutic compounds.
Pancreatic cancer is one of the most aggressive cancers with a 5-year patient survival rate of 8.2% and limited availability of therapeutic agents to target metastatic disease. Pancreatic cancer is characterized by a dense stromal cell population with unknown contribution to the progression or suppression of tumor growth. In this study, we describe a microengineered tumor stromal assay of patient-derived pancreatic cancer cells to study the heterotypic interactions of patientpancreatic cancer cells with different types of stromal fibroblasts under basal and drug-treated conditions. The population dynamics of tumor cells in terms of migration and viability were visualized as a functional end point. Coculture with cancer-associated fibroblasts increased the migration of cancer cells when compared to dermal fibroblasts. Finally, we imaged the response of a bromodomain and extraterminal inhibitor on the viability of pancreatic cancer clusters surrounding by stroma in microengineered tumor stromal assay. We visualized a codynamic reduction in both cancer and stromal cells with bromodomain and extraterminal treatment compared to the dimethyl sulfoxide-treated group. This study demonstrates the ability to engineer tumor-stromal assays with patient-derived cells, study the role of diverse types of stromal cells on cancer progression, and precisely visualize a coculture during the screening of therapeutic compounds.
Pancreatic cancer remains as one of the most aggressive types of cancers with a very poor
patient outcome.[1] Currently, gemcitabine and 5-fluorouracil are the most commonly used chemotherapeutic
compounds being used to treat patients, but there is clearly an unmet need to discover new
therapies for treating pancreatic cancer. Understanding the key components and drivers of a
pancreatic cancer microenvironment can reveal new mechanistic targets to improve cancer
therapy. Cancer cells do not live in a vacuum; they are surrounded by several cellular and
noncellular components that are emerging as major instigators of tumor growth or tumor
suppression and potential targets for therapy.[2,3] Breast, prostate, gastrointestinal, and pancreatic cancer have abundant amounts of
stromal cells when compared to other tumors.[4,5] The stromal compartment undergoes significant changes at all levels from cell phenotype,[6,7] epigenetics,[8] to gene expression profile,[5,6] which are partly accounted for by activation and transdifferentiation of local cells,
and partly by recruitment of new cell types into the tumors.[9] Therefore, ideal models for studying cancer therapeutics should be able to follow and
interrogate the natural evolution of morphological and compositional characteristics of
tumor tissue.In vivo mouse models are one of the most promising and commonly used models
to study drug efficacy within a complex stromalized tumor microenvironment.[6] Despite these properties of animal models, they are time-consuming to develop,
low-throughput, and expensive. In addition, genetics, immunological, and cellular
disparities exist between humans and mice.[10,11]
In vitro high-throughput screening of cancer cell lines with an end point
such as cytotoxicity is typically used to identify compounds of interest more rapidly.
However, these simple cancer models do not account for the heterotypic interaction between
cancer cells[7] and paracrine signaling between tumor cells and cells of the microenvironment that
can influence drug efficacy. Three-dimensional tumor spheroid models have proven to be
promising models to study drug response and tumor progression in a complex cellular environment.[12-14] To study tumor–stromal interactions, spheroid models have been developed by mixing
tumor and stromal cells can mimic cell types and the diffusion limits of a tumor mass.[15,16] However, these models do not control the spatial tumor–stromal interactions that
exist in the in vivo solid tumors. To address this issue, recent studies
have focused on the development of microfluidic and hydrogel-based approaches to study
cancer–stromal interactions. In a recent study by Hong et al, microfluidic
platforms were developed to capture cancer and stromal cells and study their interactions at
a single-cell level.[17,18] Similarly, other microfluidic approaches have aided in understanding the role of
cancer-associated fibroblasts (CAFs) on cancer cell migration[19] in creating a proangiogenic environment[20] for a cancer-stem cell niche.[21] These systems have significantly improved our understanding about the interactions
between cancer and stromal cells such as CAFs both at a single-cell level and studying their
heterotypic interactions. Despite these advantages, the scalability of microfluidic devices
to study chemotherapeutic drug response requires parallel fluid circuits and likely
automation, which is not currently standard practice in pharmaceutical screening facilities.
Thus, an in vitro model that is high throughput in microwell screening
formats, easy to fabricate, and can control the interaction of cancer cells and the cellular
components of the tumor microenvironment continues to be of value.This study expands on previously published work from our group by Shen et
al, which developed a novel in vitro microengineered
tumor-stromal assay (μTSA) platform for studying the spatial interaction of breast cancer
cell lines and fibroblasts.[22] The μTSA is a coculture system whereby cancer and stromal cells are precisely
localized using micropatterning, a technique that has been extensively developed for other
cell culture applications to study cell morphogenesis and differentiation.[23,24] Herein, we adapted μTSA to study patient-derived pancreatic cancer and stromal cells.
Furthermore, we developed new image-based end points to measure the expansion of
micropatterned tumor islands during states of migratory growth or drug treatment. The effect
of inhibiting bromodomain and extraterminal (BET) inhibitor was finally evaluated on the
population dynamics of tumor and stromal cells in μTSA.
Materials and Methods
Cells and Reagents
Patient-derived 1319-3-NE (pancreatic cancer cell line) was generated from a PDX model of
pancreatic ductal adenocarcinoma.[25] The cell line was generated and used in our study after obtaining institutional
review board approval (2003P001289) and patient consent. HPDE-6/E6E7 (pancreatic
epithelial cells) were generated using the procedure outlined in the study by Ouyang
et al.[26] JD-PDAC-CAF (pancreatic CAF) were isolated from a humanpancreatic adenocarcinoma
resected by pancreatoduodenectomy using the Bachem outgrowth method.[27] For all our experiments, we used cells from passages 1 to 6 to maintain
consistency. Cell type and purity was assessed by morphology and immunofluorescent
staining for vimentin and pan-cytokeratin as described (prognostic significance of
zinc-finger E-box binding homeobox 1) expression in cancer cells and CAFs in pancreatic
head cancer).[28]Normal human dermal fibroblasts (NHDFs) were purchased from ATCC. 1319-3-NE were
maintained in Dulbecco’s modified Eagle medium (DMEM) F12 media with 10% fetal bovine
serum (Gibco, USA) and 1% penicillin-streptomycin. HPDE-6/E6E7 cells were cultured in 1×
keratinocyte serum-free media (Gibco, USA) supplemented with pituitary bovine serum,
epithelial growth factor (EGF), and 1% penicillin-streptomycin. Both NHDF and JD-PDAC CAF
cells were cultured in DMEM media supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin. All the reagents for cell culture were purchased from
Thermofisher Scientific (USA), unless otherwise specified.For the imaging experiments, 1319-3NE, HPDE-6/E6E7 cells, NHDF, and JD-PDAC CAF were
transduced with lentivirus carrying either mCherry or EGFP reporter genes, respectively.
Lentivirus was added to cultures at multiplicities of infection in the range of 2.5 to 5.
After 48 hours, the virus-infected cells were purified using flow cytometry at the
Massachusetts General Hospital (MGH) flow cytometry core facility.
Micropattern Fabrication
A microtumor stromal assay was fabricated using the previously published method[22] and shown in schematic form in Figure 1. In brief, 12 mm diameter coverslips were cleaned and treated with
oxygen plasma (PDC-32G, Harrick Plasma, USA) for 5 minutes. Following this, they were
immersed in 1% N-(2-aminoethyl)-3-aminopropyl-trimethoxy-silane (Sigma Aldrich, USA) for
15 minutes. After a series of thorough washing, they were dried with nitrogen gas and then
incubated at 100°C for 1 hour. The silanized coverslips were treated with rat tail
collagen I extracted in lab, diluted to a concentration of 1 mg/ml in 0.1% acetic acid
overnight at 4°C. After the collagen treatment, the coverslips were air dried in a sterile
laminar flow hood and sterilized using ultraviolet for half an hour. Polydimethylsiloxane
(PDMS) stencils of varying circle diameters (P1-P4) were prepared using the previously
published protocol.[22] The stencils of format P2 was used throughout the study unless specified. They were
mounted on collagen-coated coverslips and treated for 1 hour in 0.2% (w/v) Pluronic F-127
(Sigma Aldrich, USA) in phosphate-buffered saline (PBS) followed by washing with PBS.
Pluronic treatment was done on the micropatterns to prevent protein adhesion in regions
other than the PDMS stencil.[29] The tumor–stromal micropatterns were established following the steps illustrated in
Figure 1. Cancer and/or
epithelial cells were seeded at a density of 0.3 × 106 cells/micropattern and
incubated in keratinocyte serum-free media at 37°C for 2 hours. Following this incubation,
the patterns were washed with warm media. The stencils were then incubated at 37°C and 5%
CO2 overnight. For the experiments with monoculture cells, the stencils were
removed, and time-dependent imaging was performed over a period. In the case of the
microtumor stromal assay, the stencils were removed and NHDF GFP/PDAC CAF GFP cells were
seeded at a density of 80 000 cells/ micropattern and incubated in keratinocyte serum-free
media at 37°C for 1 hour. Following this incubation, the patterns were washed with warm
media to remove fibroblast/CAF cells adhering on the cancer/epithelial islands. The
patterns were then incubated overnight at 37°C and 5% CO2. After stabilization
of the micropatterns overnight, the media are switched to DMEM F12 containing 10% FBS and
1% pen-strep. The micropatterns were cultured in these media till day 5 with a 10% media
change every day.
Figure 1.
Generation of tumor–stromal micropatterns. Schematic representation of generating the
micropatterns using PDMS stencils and epithelial/cancer cells (islands) surrounded by
NHDF/CAF (stromal cells). CAF indicates cancer-associated fibroblast; NHDF, normal
human dermal fibroblast; PDMS, polydimethylsiloxane.
Generation of tumor–stromal micropatterns. Schematic representation of generating the
micropatterns using PDMS stencils and epithelial/cancer cells (islands) surrounded by
NHDF/CAF (stromal cells). CAF indicates cancer-associated fibroblast; NHDF, normal
human dermal fibroblast; PDMS, polydimethylsiloxane.
Determination of Migration of Cells in the Micropattern
The micropatterns of cancer/epithelial cells from the islands were imaged every 24 hours
for a period of 3 days using the Axio Zoom V.16 (Zeiss). In the case of monoculture
patterns, the migration of cancer and epithelial cells in the absence of stroma was
determined. The percent area of cancer islands was determined by selecting the mCherry
channel images and analyzing the images using NIH imageJ (version 1.51) following the
steps outlined in Figure S1A. Thus, by imaging the same island over time and measuring the
percent of cancer cells, the increase in island area (migration) was estimated.For the micropatterns consisting of cancer cells cocultured with NHDF/CAFs, the migration
of cells was characterized in 2 ways using NIH ImageJ software: (1) the number of
CAFs/NHDFs within the cancer island and (2) total percent of fibroblasts in the
micropattern. For the first method, the number of CAFs/NHDFs within the cancer island were
determined by selecting the GFP channel images and analyzing using ImageJ software.
Thresholding and island area selection were performed using the steps outlined in Figure
S1B. For the second method, the total percent CAFs/NHDF in the micropattern was determined
by selecting the GFP channel images. The thresholding and area selection were performed to
select the entire area of the image and the percent CAFs/NHDFs was estimated. For both
these methods, images of the same islands over time were captured and image analysis was
performed. Thus, the analysis over time provided the percent CAFs/NHDF or number of
fibroblast over time.
Pharmacological Treatment of Cancer Cell Cocultures
The BET inhibitor, CPI 203 (Constellation Pharmaceuticals, USA) at a concentration of 1.4
μM was added to the micropatterns with cancer cells cocultured with CAFs. The control
micropatterns were treated with dimethyl sulfoxide (DMSO). The migration of cancer cells
in the control and drug-treated group was determined by tracking the micropatterns over
time and analyzing the island size NIH ImageJ as described above.
Statistics
The results are reported as mean (standard deviation; n = 4-6 islands from 2 to 3
independent experiments). Statistical significance between multiple groups was calculated
using 1-way or 2-way analysis of variance for multiple comparisons followed by Tukey post
hoc analysis (Graphpad prism, version 6). P values less than .05 were
considered statistically significant.
Results
Increased Migration of Patient Pancreatic Cancer Cells Compared to Normal
Patient-Derived Epithelial Cells
The μTSA was first tested to develop analytical methods to study circumferential cell
migration as a new quantitative end point of the assay. The inherent migratory potential
of the patient-derived cancer cell line 1319-3-NE was first studied in μTSA using islands
of cancer cells in the absence of any stromal cells. A noncancerous cell line was also
derived from pancreatic epithelial cells (HPDE6/E7) as a normal epithelial cell control.
To facilitate tracking of cell migration, HPDE6 and 1319-3-NE cells were infected with
lentivirus that express mCherry-fluorescent protein. Cancer or epithelial islands were
formed using the PDMS stencils mounted on collagen-coated coverslips. After 24 hours, the
PDMS stencils were removed and the migration of cancer and epithelial cells from their
respective micropattern was imaged at 3, 24, and 48 hours as shown in Figure 2A. The extent of migration was quantified
using ImageJ analysis as shown in Figure
2B. The migration of cancer cells was significantly greater than normal
epithelial cells by 48 hours (P ≤ .05). This result qualified this end
point assay for the study of migration between cancerous cells and their normal
counterparts.
Figure 2.
Migration of normal patient-derived epithelial cells versus cancer cells. Pancreatic
epithelial cells (HPDE6/E6E7) expressing mCherry and pancreatic cancer cells
(1319-3-NE) were seeded on PDMS stencils to form respective epithelial/cancer islands.
A, Fluorescent images of the micropatterns taken at different time points ranging from
3 to 48 hours. B, ImageJ analysis of percent area occupied by cancer/epithelial cells
at each time point in terms of data (SD; n = 5-6 cancer/epithelial islands). * denotes
statistical significance when compared to the control epithelial island
(P < .05). PDMS indicates polydimethylsiloxane; SD, standard
deviation.
Migration of normal patient-derived epithelial cells versus cancer cells. Pancreatic
epithelial cells (HPDE6/E6E7) expressing mCherry and pancreatic cancer cells
(1319-3-NE) were seeded on PDMS stencils to form respective epithelial/cancer islands.
A, Fluorescent images of the micropatterns taken at different time points ranging from
3 to 48 hours. B, ImageJ analysis of percent area occupied by cancer/epithelial cells
at each time point in terms of data (SD; n = 5-6 cancer/epithelial islands). * denotes
statistical significance when compared to the control epithelial island
(P < .05). PDMS indicates polydimethylsiloxane; SD, standard
deviation.
Increased Interfacial Interactions Between Tumor and Stroma Can Cause an Invasive
Switch
Pancreatic cancer has a large number of fibroblastic cells contributing to the tumor
microenvironment. Hence, we investigated the behavior of tumor cells in the presence of
fibroblasts. For these experiments, we used NHDF cells that were engineered to express GFP
using lentivirus. The goal of this study was to evaluate the migration of cancer cells
with increasing amounts of heterotypic interaction with neighboring fibroblasts. Stencils
of different circle diameters (P1-P4) were used for this experiment, which assured that
the same total number of tumor and fibroblastic cells were maintained on each pattern
(Figure 3A). The total area of
all the circles in each stencil type remained constant; however, the individual area of
each circle was different in the patterns P1 to P4, with P1 having the largest area and P4
being the smallest in terms of cancer cells per island. Owing to the differences in the
number of circles in the stencils, P4 had the highest surface area of interaction between
cancer and stromal cells as shown in Figure 3B. The migration of cancer cells in the presence of NHDF cells in the
stencils P1 to P4 was tracked over a period of 4 days with the highest migration of cancer
islands taking place in P4 patterns with the most amount of heterotypic stromal
interaction (Figure 3C). A
disorganized and invasive morphology was observed in P4 whereas most other patterns
maintained a relatively circular migration pattern. These studies confirm a stark increase
in cell migration that is primarily instigated by more interfacial interaction with NHDFs
rather than a total number of stromal cells.
Figure 3.
Pancreatic cancer cells (1319-MP3-NE mCherry) were seeded in PDMS stencils of varying
circle diameters (P1-P4) and cocultured with normal dermal fibroblast (NHDF-GFP). P1,
P2, P3, and P4 were 3, 1.5, 0.75, and 0.375 mm, respectively; center-to-center
distances were 4, 2, and 1 mm for P2, P3, and P4, respectively. A, Representative
fluorescent images of the micropatterns taken at different time points from day 1 to
day 4. B, Quantification of the total tumor–stromal interfacial area in each stencil
type. C, Migration of cells from the cancer islands using stencils with different
tumor–stromal interfacial areas calculated using ImageJ analysis of the images taken
at different time points. The increased interfacial area in P4 correlates with the
increase in migration of cells. The figure represents data (SD; n = 3-4
micropatterns/condition). * denotes statistical significance when compared to the P1
micropattern (P < .05). PDMS indicates polydimethylsiloxane; SD,
standard deviation.
Pancreatic cancer cells (1319-MP3-NE mCherry) were seeded in PDMS stencils of varying
circle diameters (P1-P4) and cocultured with normal dermal fibroblast (NHDF-GFP). P1,
P2, P3, and P4 were 3, 1.5, 0.75, and 0.375 mm, respectively; center-to-center
distances were 4, 2, and 1 mm for P2, P3, and P4, respectively. A, Representative
fluorescent images of the micropatterns taken at different time points from day 1 to
day 4. B, Quantification of the total tumor–stromal interfacial area in each stencil
type. C, Migration of cells from the cancer islands using stencils with different
tumor–stromal interfacial areas calculated using ImageJ analysis of the images taken
at different time points. The increased interfacial area in P4 correlates with the
increase in migration of cells. The figure represents data (SD; n = 3-4
micropatterns/condition). * denotes statistical significance when compared to the P1
micropattern (P < .05). PDMS indicates polydimethylsiloxane; SD,
standard deviation.
Type of Stroma Dictates the Tumor Progression
Cancer tissue is heterogeneous with different types of stromal cells localized in the
tumor microenvironment.[30] To study the role of specific fibroblastic subtypes, we studied the response of
1319-3-NE cells cocultured with normal fibroblasts versus CAFs and measured the migration
of tumor cells. These experiments employed a μTSA pattern (P2) in which NHDFs had minimal
effects on cancer cell migration. As shown in Figure 4A, the migration of cancer cells in the
presence of JD-PDAC CAFs is higher when compared to the NHDF coculture by 48 hours and
quantified by image analysis of the area of the cancer island per high image field (Figure 4B).
Figure 4.
Stromal type instigates cancer migration. Pancreatic cancer cells (1319-MP3-NE
mCherry) were seeded in PDMS stencils and cocultured with normal dermal fibroblast
(NHDF-GFP) or patient-derived pancreatic cancer associated fibroblast (CAF-GFP). A,
Fluorescent images of the micropatterns taken at different time points ranging from 24
to 72 hours. The presence of CAFs increase the migration of cancer cells. B, C, ImageJ
analysis on the images in terms of data (SD; n = 5-6 cancer islands). * denotes
statistical significance when compared to the NHDF group (P <
.05). PDMS indicates polydimethylsiloxane; SD, standard deviation.
Stromal type instigates cancer migration. Pancreatic cancer cells (1319-MP3-NE
mCherry) were seeded in PDMS stencils and cocultured with normal dermal fibroblast
(NHDF-GFP) or patient-derived pancreatic cancer associated fibroblast (CAF-GFP). A,
Fluorescent images of the micropatterns taken at different time points ranging from 24
to 72 hours. The presence of CAFs increase the migration of cancer cells. B, C, ImageJ
analysis on the images in terms of data (SD; n = 5-6 cancer islands). * denotes
statistical significance when compared to the NHDF group (P <
.05). PDMS indicates polydimethylsiloxane; SD, standard deviation.In addition to the migration of the cancer cells, we observed an expansion of fibroblasts
into cancer islands. This expansion of fibroblasts was calculated based on the number of
NHDFs/CAFs located inside the cancer island over time. In contrast to their differential
effects on the migration of 1319-3-NE cells, both normal dermal fibroblasts and CAFs
increased in number in the cancer island with comparable efficiency (Figure 4C). This system can not only be used in
studying the role of different stromal cells on functional endpoint like migration but
also provide an insight on the 2-way cellular interactions of fibroblasts that likely
occurs within a tumor microenvironment.
Bromodomain and Extraterminal Inhibition Impacts Both Tumor and Stroma in a
Spatiotemporal Manner
Members of the BET domain family of chromatin adaptors (BRD2, BRD3, and BRD4) play key
roles promoting the growth of both the neoplastic and stromal cells in PDAC tumors.[13] For validating the μTSA model as a drug screening platform, we cultured the
1319-3-NE cancer cells with CAFs and evaluated the pan-BET inhibitor, CPI203, that
prevents the binding of the BET proteins to their targets acetylated lysines on histones.
CPI203 has been shown to dramatically reduce pancreatic cancer growth in
vitro and in vivo by Huang et al,[31] though it is unknown what CPI203 does to stromal cells. After stabilizing the
micropattern culture for 24 hours with serum-containing media, the patterns were divided
into 2 groups, one treated with BET inhibitor 1.4 μM and the other with DMSO control. The
concentration of this drug was chosen based on the dose–response curve for the viability
of cancer cells treated with CPI203 treated for 5 days (Figure S2). Patterns treated with
BET inhibitor showed a decrease in the size of cancer island area over a period of 72
hours (Figure 5A). In DMSO-treated
groups, cancer islands continued to grow and CAFs were evident. The area of cancer islands
in the BET inhibitor treated group was 20.63% (3.41%) when compared to a 68.13% (7.92%) in
the DMSO-treated group at 48 hours (Figure 5B). Interestingly, the total number of CAFs were also eliminated by the
treatment within a similar timescale (Figure 5C). These results demonstrate the applicability of μTSA model to
spatially study multiple cell populations during drug exposure.
Figure 5.
Pharmacological inhibition of growth using BET inhibitor. μTSA of patient-derived
pancreatic cancer and CAF cells treated with 1.4 μM BET inhibitor or DMSO controls. A,
Representative images of the micropatterns taken before and after BET inhibitor/DMSO
at different time points. B, ImageJ analysis of the percent area occupied by the
cancer cells over time following DMSO/drug treatment. Treatment with BET inhibitor
decreased the viability of cancer cells by approximately 60% marked by the shrinking
of cancer islands. C, ImageJ analysis of percent area occupied by the cancer
associated fibroblast in the whole micropattern. The ImageJ quantification represented
here are based on average (SD; n = 5-6 cancer islands/condition) and *, **, and ***
represent statistical significance when compared to the control DMSO-treated group at
the respective time points. BET indicates bromodomain and extraterminal; CAF,
cancer-associated fibroblast; DMSO, dimethyl sulfoxide; SD, standard deviation; μTSA,
microengineered tumor stromal assay.
Pharmacological inhibition of growth using BET inhibitor. μTSA of patient-derived
pancreatic cancer and CAF cells treated with 1.4 μM BET inhibitor or DMSO controls. A,
Representative images of the micropatterns taken before and after BET inhibitor/DMSO
at different time points. B, ImageJ analysis of the percent area occupied by the
cancer cells over time following DMSO/drug treatment. Treatment with BET inhibitor
decreased the viability of cancer cells by approximately 60% marked by the shrinking
of cancer islands. C, ImageJ analysis of percent area occupied by the cancer
associated fibroblast in the whole micropattern. The ImageJ quantification represented
here are based on average (SD; n = 5-6 cancer islands/condition) and *, **, and ***
represent statistical significance when compared to the control DMSO-treated group at
the respective time points. BET indicates bromodomain and extraterminal; CAF,
cancer-associated fibroblast; DMSO, dimethyl sulfoxide; SD, standard deviation; μTSA,
microengineered tumor stromal assay.
Discussion
New models that account and control for the stromal component of a tumor microenvironment
can provide new insight into cancer biology. Characteristic of pancreatic adenocarcinoma is
a highly desmoplastic stroma, composed of abundant fibrosis, CAFs, leaky abnormal blood
vessels, and infiltrating immune cells.[32] This pronounced stromal desmoplasia not only promotes the aggressive local growth of
the tumor and the intrinsic chemoresistance of cancer cells[33,34] but also acts as a physical barrier to effective chemotherapeutic targeting.[35,36] Much of the focus of the tumor microenvironment of PDAC has been on the cellular
components, revealing that CAFs promote tumor formation during early tumor development, but
serve to restrain cancer cell growth in established tumors.[37-40] This study evaluated a desmoplastic coculture of patient-derived tumor cells with a
focus on imaging population dynamics in a spatially controlled micropatterned culture.We first validated enhanced migratory potential of patient-derived cancer cells compared to
their epithelial cell controls. The use of μTSA for cell migration studies is beneficial
because of the opportunity to visualize tumor cells in real-time during an “invasion”
process into a stromal compartment. In comparison, commonly used systems such as Boyden
chamber assay to determine migration of cancer cells in the presence of chemoattractants do
not account for cell–cell contact and real-time tracking of cell migration cannot be
accomplished using this method.[41] Furthermore, we also could study the fate of fibroblasts into a tumor bed. Although
it is unclear whether fibroblasts migrated into the cancer island from the periphery or a
small initial population initially embedded in the cancer island grow within the pattern,
stromal penetration into tumors is a critical process that is actively driven by tumor cells
to shape their microenvironment into a growth supportive and immunosuppressive environment
which can be specifically explored in future studies.Using μTSA, we could study, for the first time, the amount of heterotypic interfacial
interactions and its influence on cancer cell migration. By varying island density with a
fixed number of total cancer and stromal cells, our studies indicate that the increase in
tumor–stromal interfacial area led to increased aggressiveness of the tumor at a specific
tipping point. From our previously published study with MDA-MB231 breast cancer cells
cocultured with NHDF in patterns with varying stencil patterns, we observed a contact
mediated increase in chemokine (C-C motif) ligand 5 (CCL5) and interleukin-6 (IL6)
activation of stromal cells by cancer cells. The increase in interfacial surface area
correlated with an increase in CCL5 and IL6.[22] Growth factors such as tumor growth factor-β1, C-X-C motif chemokine 12,[42] platelet-derived growth factor-α/β,[43] and IL6 secreted by cancer cells are involved in the activation of fibroblast in the
tumor stroma. The loss of critical tumor suppressor genes such as PTEN,
CAV-1,[43]
p53, and p21 in resident fibroblast of the tumor are also
involved in the activation process.[43] Franci et al demonstrated that SNAIL, an important protein that is
involved in epithelial–mesenchymal transition and invasion of tumor cells, is upregulated at
the tumor–stromal interface.[44] Collectively, these results suggest that the co-opting of a normal fibroblast
phenotype into a CAF phenotype may occur at a critical point at which interfacial
interactions go beyond a threshold. Genomic profiling of fibroblasts in different patterns
for changes in activation genes is warranted in future studies.The type of fibroblastic stroma was prospectively studied in μTSA with patient-derived
cancer cells where it was observed that CAFs instigate tumor migration more so than NHDFs. A
study by Gao et al demonstrated that MDA-MB321 cells cultured with
conditioned media from fibroblasts isolated CAFs from a tumor–stromal interface showed
increased tumor migration when compared to the cocultures with normal fibroblast media.[45] Similarly, a study by Shan et al probed into the invasiveness of
pancreatic cancer cell lines PANC-1 and BxPc-3 in the presence of CAF/normal fibroblast
conditioned media using transwell and scratch assay, respectively. In both these assays,
CAFs promoted the migration and invasion of cancer cells.[46] Thus, these studies showed similar trends of CAF instigating cancer cell migration
using invasion assays.The BET family of chromatin adaptors plays a key role in regulating the expression of the
matrix molecules in both stromal and cancer cells of patient-derived xenograft tumors.[31]
In vivo antitumor effects of BET inhibitors were rather dependent on the
suppression of tumor-promoting activity in CAFs.[47] Our study visualized the co-evolution of BET inhibition on both tumor and stromal
cells and found a striking and concordant loss of both cells types in response to BET
blockade. Uncoupling of the spatial and temporal dynamics of this response in each cell type
can be an important follow-up to understand the multistep process by which BET inhibitors
act.In conclusion, we adapted and evolved μTSA for use with patient-derived cells. This
controlled coculture method revealed important triggers of tumor cell viability and growth
that included the type of stroma, amount of heterotypic interaction, and coordinated
response to a small molecule inhibitor that was enabled by having precise control of
tumor–stromal interactions.Click here for additional data file.Supplimentary_fig_(1) for Image-Based Profiling of Patient-Derived PancreaticTumor–Stromal Cell Interactions Within a Micropatterned Tumor Model by Shilpaa Mukundan,
Kriti Sharma, Kim Honselmann, Amy Singleton, Andrew Liss, and Biju Parekkadan in
Technology in Cancer Research & TreatmentClick here for additional data file.Supplimentary_fig_S2_(1) for Image-Based Profiling of Patient-Derived PancreaticTumor–Stromal Cell Interactions Within a Micropatterned Tumor Model by Shilpaa Mukundan,
Kriti Sharma, Kim Honselmann, Amy Singleton, Andrew Liss, and Biju Parekkadan in
Technology in Cancer Research & Treatment
Authors: Yinshi Huang; Sabikun Nahar; Akifumi Nakagawa; Maite G Fernandez-Barrena; Jennifer A Mertz; Barbara M Bryant; Curtis E Adams; Mari Mino-Kenudson; Kate N Von Alt; Kevin Chang; Andrew R Conery; Charlie Hatton; Robert J Sims; Martin E Fernandez-Zapico; Xingpeng Wang; Keith D Lillemoe; Carlos Fernández-Del Castillo; Andrew L Warshaw; Sarah P Thayer; Andrew S Liss Journal: Clin Cancer Res Date: 2016-05-11 Impact factor: 12.531
Authors: Min Hu; Jun Yao; Li Cai; Kurt E Bachman; Frédéric van den Brûle; Victor Velculescu; Kornelia Polyak Journal: Nat Genet Date: 2005-07-10 Impact factor: 38.330
Authors: Carolyn E Clark; Sunil R Hingorani; Rosemarie Mick; Chelsea Combs; David A Tuveson; Robert H Vonderheide Journal: Cancer Res Date: 2007-10-01 Impact factor: 12.701
Authors: Shannon Kidd; Erika Spaeth; Keri Watson; Jared Burks; Hongbo Lu; Ann Klopp; Michael Andreeff; Frank C Marini Journal: PLoS One Date: 2012-02-20 Impact factor: 3.240
Authors: Karen M Bussard; Lysette Mutkus; Kristina Stumpf; Candelaria Gomez-Manzano; Frank C Marini Journal: Breast Cancer Res Date: 2016-08-11 Impact factor: 6.466